Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
<p dir="ltr">Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New approaches for the genetic engineering of immune effector cells with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B, respectively) have led...
محفوظ في:
| المؤلف الرئيسي: | Francisco Martin (26407) (author) |
|---|---|
| مؤلفون آخرون: | Axel Schambach (214256) (author), Cristina Maccalli (2632465) (author) |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
حسب: Gunjan Dagar (9339276)
منشور في: (2023) -
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
حسب: Remy Thomas (702843)
منشور في: (2018) -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
حسب: Ghaneya Al-Khadairi (14153274)
منشور في: (2019) -
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
حسب: Remy Thomas (702843)
منشور في: (2020) -
Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients
حسب: Salman M. Toor (8854751)
منشور في: (2019)